Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145431
Status:
TERMINATED
Last Update Posted:
2012-02-17
First Post:
2005-08-31
Brief Title:
Study To Evaluate The Effect Of TorcetrapibAtorvastatin In Subjects With A Genetic Cholesterol Disorder
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Multi-Center Double-Blind Randomized Crossover Study Of The Efficacy Safety And Tolerability Of Fixed Combination Torcetrapib Cp-529414Atorvastatin Compared With Atorvastatin Therapy Alone And Fenofibrate Alone In Subjects With Fredrickson Type III Hyperlipoproteinemia Familial Dysbetalipoproteinemia
Status:
TERMINATED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Torcetrapib project was terminated on December 2 2006 due to safety findings
To evaluate the efficacy and safety of the lipid drug torcetrapibatorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels
To evaluate the efficacy and safety of the lipid drug torcetrapibatorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels
Detailed Description:
For additional information please call 1-800-718-1021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None